HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3

• http://ow.ly/zQ7B50F3Gag

@alberta_hoi @earlyarthritis @RheumNow Indeed. The #EULAR2021 session on this is one I have to go back and watch! https://t.co/0kLLQVbyWl

Reassuring safety data from @rheum_covid COVAX registry on #COVID #vaccination in patients with #RMDs 👉🏼Vaccine welltolerated by most patients 👉🏼Most adverse events similar to gen population 👉🏼RMD flares were rare after vaccine 👉🏼#GetVaccinated! LB0002 @pedrommcmachado #EULAR2021 https://t.co/bheIcVZ9xa

🤜MTX safe from kidney perspective if baseline CrCl 40+ 🤜Potential for immunomodulation to prevent/slow progression to CKD? Deserves dedicated studies @Nephro_Sparks

Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow

“Let thy food by thy medicine and thy medicine be thy food” Western diet - greatest enemy of chronic inflammatory conditions? ⬆️salt ⬆️refined carbs ⬆️omega 6 fatty acids ⬇️fiber, long chain omega 3 FA Abs#OP6882 #EULAR2021 @RheumNow

Dr Schapp on nasal Staph Aureus eradication in ANCA vasculitis. Neither the presence or eradication of Staph Aureus appeared to influence the vasculitis @RheumNow #EULAR2021 Abstr#POS0249 https://t.co/bxtaznejNk

Practical tip from #EULAR2021 Pres6882: The difference a double bond makes: ⭐️Omega-3: Anti-inflammatory! ⭐️Omega-6: Pro-Inflammatory The ratio of ⬆️ omega-3 : ⬇️ omega-6 is key to anti-inflammatory diet @Rheumnow https://t.co/RtGWsDIouC

A giant in our field. He has been my teacher for most of my career (since fellowship). He taught me how to care for patients, conduct research, & teach. My favorite quote is "If you're doing nothing, you're not doing anybody any good!" What is something he taught you? @rheumnow https://t.co/Fyw1u8wln8

• https://twitter.com/UTSWRheum/status/1401156663831371785

Would you use #Telemedicine (TM) to follow-up #SLE patients post #COVID? Dr So showed in an RCT (N=122),patient satisfaction and time-to-review were better in TM vs Face-to-Face. Although none had COVID, >pts in TM were hospitalised and trend to⬆️FU #EULAR2021 #POS1164 @RheumNow https://t.co/p7aWv4AVm7

@almirall_m I don't monitor routinely. High rate of seroconversion post-TNFi but only small cases of TNFi-induced SLE (mild mostly). To screen with ANA if develop SLE features

Apremilast in Behcet’s - RELIEF European subgroup analysis ⬇️oral ulcer count, ulcer pain, disease activity ⬆️QoL ⭐️results consistent with general population Abs#POS0254 #EULAR2021 @RheumNow https://t.co/NVGt4TjkYY

Dr Marsman presents positive RCT of Rituximab in PMR. GC-free remission 48% vs 21% (p=0.049) GC<=5mg 100% vs 47% (p=0.005) @RheumNow #EULAR2021 Abstr#POS0343 https://t.co/tjkKTS6DMN

Gut dysbiosis linked to worse disease status in AxSpA ⭐️higher dysbiosis associated w/ worse EvalGlobal, ASDAS-CRP, BASDAI, BASFI, VAS pain ⭐️comparing dysbiosis vs. non-dysbiosis group - significant difference in BASDAI, BASFI, EvalGlobal Abs#POS0237 #EULAR2021 @RheumNow

Looking at those results (distributed evenly each side of 'maybe a little') it seems we're collectively uncertain right now about what JAK1 selectivity really means in practice. Hopefully we get stronger clinical insights (toxicity/efficacy) in coming years! #EULAR2021 @RheumNow https://t.co/jFhVGqpOnb

• https://twitter.com/drdavidliew/status/1400831933123239944